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ABSTRACT 
 
Currently available methods for detection of tumors in vivo such as X-ray, 
computed tomography, and ultrasonography are noninvasive and well studied; the 
images, however, are not specific for tumors. Direct optical imaging of tumor cells in 
vivo that can clearly distinguish them from surrounding normal tissues may be 
clinically useful. Here, we describe a new approach to visualizing tumors whose 
fluorescence can be detected using tumor-specific replication-competent adenovirus 
(OBP-301, “Telomelysin”) in combination with replication-deficient adenovirus 
expressing GFP (Ad-GFP). Human telomerase reverse transcriptase (hTERT) is the 
catalytic subunit of telomerase, which is highly active in cancer cells, but is quiescent in 
most normal somatic cells. We constructed an adenovirus 5 vector, in which the hTERT 
promoter element drives expression of E1A and E1B genes linked with an IRES, and 
showed that OBP-301 replicated efficiently exclusively in human cancer cells, but not 
in normal cells such as human fibroblasts. When the human lung and colon cancer cell 
lines H1299 and SW620 were infected with Ad-GFP at low multiplicity of infection 
(MOI), GFP expression could not be detected under a fluorescence microscope; in the 
presence of OBP-301, however, Ad-GFP replicated in these tumor cells and showed 
strong green signals. In contrast, co-infection of OBP-301 and Ad-GFP did not show 
any signals in normal cells such as WI-38 fibroblasts. We also found that established 
subcutaneous tumors could be visualized following intratumoral injection of OBP-301 
and Ad-GFP. A549 human lung tumors and SW620 human colon tumors transplanted 
into BALB/c nu/nu mice were intratumorally injected with 8 x 105 plaque forming units 
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(PFU) of Ad-GFP in combination with 8 x 106 PFU of OBP-301. Within 3 days of 
treatment, the fluorescence of the expressed GFP became visible by 3CCD camera in 
these tumors, whereas intratumoral injection of Ad-GFP alone could not induce GFP 
fluorescence. Moreover, intrathoracic administration of Ad-GFP and OBP-301 could 
visualize disseminated A549 tumor nodules in mice following intrathoracic 
implantation. Our results indicate that intratumoral or intrathoracic injection of 
Ad-GFP in combination with OBP-301 might be a useful diagnostic method that 
provides a foundation for future clinical application.  
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INTRODUCTION 
 
A variety of imaging technologies is being investigated as tools for cancer 
diagnosis, detection, and treatment monitoring. Improvements in methods of external 
imaging such as computed tomography (CT), magnetic resonance imaging (MRI), and 
ultrasound techniques have increased the sensitivity for visualizing tumors and 
metastases (1, 2); a limiting factor in structural and anatomical imaging, however, is the 
inability to specifically identify malignant tissues. Histopathological examination is 
still the most effective method for the detection of neoplastic lesions. Thus, 
tumor-specific imaging would be of considerable value in treatment of human cancer 
by defining the location and area of tumors without microscopic analysis. In particular, 
if tumors too small for direct visual detection and therefore not detectable by direct 
inspection could be imaged in situ, surgeons could precisely excise tumors with 
appropriate surgical margins. This paradigm requires an appropriate “marker” that can 
facilitate visualization of physiological or molecular events that occur in tumor cells but 
not normal cells.  
Molecular and functional monitoring of cellular processes has become a reality 
with the development of the green fluorescent protein (GFP)3 technology, which was 
originally identified from the jellyfish Aequorea Victoria (3-5). GFP is able to 
specifically label biological molecules and cellular structures, and can be sensitively 
detected by a variety of optical techniques. These labels can be detected in living tissues 
because of the relatively non-invasive nature of fluorescence, thus allowing transient 
and dynamic events to be visualized and measured (6-10). In addition, as GFP is 
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genetically encoded, cells can be labeled by introducing the exogenous GFP gene. 
Indeed, Yang et al. have shown that GFP-expressing tumors growing and metastasizing 
in intact animals could be viewed externally with a whole-body optical imaging system 
(11). Moreover, transgene expression could be also monitored by utilizing an 
adenovirus vector expressing the GFP gene. These observations indicate that the 
GFP-based approach might be feasible as well as practical for real-time tumor imaging 
in living mammalians.  
To specifically distinguish tumors from normal tissues, an appropriate strategy 
to make tumor cells selectively fluorescent is required. We previously constructed the 
tumor-specific replication-selective adenovirus (OBP-301, “Telomelysin”), in which 
the human telomerase reverse transcriptase (hTERT) promoter element drives 
expression of E1A and E1B genes linked with an internal ribosome entry site (IRES), 
and demonstrated the selective replication and the antitumor effect in human cancer 
cells in vitro and in vivo (12). As more than 85% of human cancer cells, but not most 
somatic normal cells, display telomerase activity (13, 14), we hypothesized that 
OBP-301 infection could complement E1 gene functions and facilitate replication of 
E1-deleted replication-deficient vectors selectively in tumor cells when co-infected.  
In the present study, using a replication-deficient adenovirus expressing the GFP 
gene in combination with OBP-301, we demonstrate a real-time fluorescence optical 
imaging of pleural dissemination of human non-small cell lung cancer cells in an 
orthotopic murine model. This novel molecular imaging technique could be feasible for 
in vivo detection of disseminated small tumor nodules.  
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MATERIALS AND METHODS 
 
Cells and Culture Conditions. The human non-small cell lung cancer cell lines 
H1299, H358, and H226Br and the human colorectal carcinoma cell lines SW620, 
LoVo, and DLD-1 were routinely propagated in monolayer culture in RPMI 1640 
medium supplemented with 10% FCS. The human non-small cell lung cancer cell line 
A549 was cultured in Dulbecco’s Modified Eagle Medium (DMEM) containing 
Nutrient Mixture (Ham’s F12). The transformed embryonic kidney cell line 293 was 
grown in DMEM containing high glucose (4.5 g/l) and supplemented with 10% FCS. 
The normal human lung diploid fibroblast cell line WI38 (JCRB0518) was obtained 
from the Health Science Research Resources Bank (HSRRB, Japan), and grown in 
Eagle’s minimal essential medium with 10% FCS. The normal human lung fibroblast 
cell line NHLF was purchased from TaKaRa Biomedicals (Kyoto, Japan) and cultured 
in the medium recommended by the manufacturer. The human umbilical vascular 
endothelial cell line HUVEC was kindly provide by Dr. Masayoshi Namba (Okayama 
University, Okayama, Japan) and propagated in monolayer culture in CSC certified 
medium with 100 units/ml penicillin and 100 mg/ml streptomycin. 
Recombinant Adenoviruses. The recombinant replication-selective, 
tumor-specific adenovirus vector was previously constructed and characterized (12). 
The resultant virus was named OBP-301 (“Telomelysin”). The adenoviral vector 
containing GFP cDNA (Ad-GFP) was also used. Viral stocks were quantified by a 
plaque-forming assay using 293 cells and stored at -80oC. 
Quantitative Real-time PCR Analysis. Total RNA from the tumor samples 
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and cultured cells was obtained using the RNeasy Mini Kit (Qiagen, Chatsworth, CA). 
Approximately 0.1 µg of total RNA was used for reverse transcription. Reverse 
transcription was performed at 22°C for 10 min and then at 42°C for 20 min. The 
hTERT mRNA copy number was determined by real-time quantitative RT-PCR using a 
LightCycler instrument and a LightCycler DNA TeloTAGGG Kit (Roche Molecular 
Biochemicals, Indianapolis, IN). PCR amplification began with a 60-sec denaturation 
step at 95°C and then 40 cycles of denaturation at 95°C for 15 sec, annealing at 58°C for 
10 sec, and extension at 72°C for 9 sec.  
Fluorescent Microscopy. Human cancer cell lines (SW620, A549, and H1299) 
and normal cells (WI-38, NHLF, and HUVEC) were infected with either 0.1 
multiplicity of infection (MOI) of Ad-GFP alone or in combination with 1 MOI of 
OBP-301 in vitro. Expression of the GFP gene was assessed and photographed (× 200 
magnification) by an Eclipse TS-100 fluorescent microscope (Nikon, Tokyo, Japan) 24 
hours after infection.  
Animal Experiments. The experimental protocol was approved by the Ethics 
Review Committee for Animal Experimentation of our institution. SW620 and A549 
xenografts were produced on the back in 5-week-old female BALB/c nu/nu mice by 
subcutaneous injection of 5 × 106 SW620 or A549 cells in 500 µl of Hank’s balanced 
salt solution (HBSS). Three weeks after tumor cell inoculation, both tumors were 
intratumorally injected with either Ad-GFP (8 × 105 PFU/50 µl) alone or Ad-GFP (8 × 
105 PFU/25 µl) plus OBP-301 (8 × 106 PFU/25 µl). Mice were anesthetized by 
intraperitoneal injection of pentobarbital (50 mg/kg) on days 1, 2, 3, 7, and 14 after 
virus injection, and examined for GFP expression. As the control, viruses were 
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subcutaneously injected into non-tumor-bearing mice. To generate an orthotopic model 
of pleural dissemination, female BALB/c nu/nu mice were intrathoracically injected 
with cell suspension of A549 cells at a density of 5 × 106 cells/200 µl through a 
27-gauge needle. Two weeks later, 4 × 107 PFU/50 µl of Ad-GFP and 4 × 107 PFU/50 
µl of OBP-301 were injected into the thoracic space by the same technique. Five days 
after virus injection, mice were sacrificed and their thoracic spaces were examined.  
Cooled Charged-coupled Device (CCD) Imaging. In vivo GFP fluorescence 
imaging was acquired by illuminating the animal with a Xenon 150 W lamp. The 
re-emitted fluorescence was collected through a long pass filter on a Hamamatsu C5810 
3-chip color CCD camera (Hamamatsu Photonics Systems, Hamamatsu, Japan). 
High-resolution image acquisition was accomplished using an EPSON PC. Images 
were processed for contrast and brightness with the use of Adobe Photoshop 4.0.1J 
software.  
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RESULTS 
 
 hTERT Levels in Human Cancer and Normal Cells. Telomerase is a novel 
marker for malignant diseases (15). To confirm the specificity of telomerase activity in 
human cancer cells, expression of hTERT mRNA, which plays a key role in telomerase 
activation (16), was measured in a panel of human tumor and normal cell lines using a 
real-time RT-PCR method. All tumor cell lines, including human non-small cell lung 
cancer A549, H226Br, and H1299 cell lines and human colorectal cancer SW620, 
LoVo, and DLD-1 cell lines, expressed detectable levels of hTERT mRNA, although 
the levels of expression varied widely (Fig. 1A). In contrast, human fibroblast cells such 
as WI38 and NHLF were negative for hTERT expression. HUVEC transformed with 
the SV40 large T-antigen gene also exhibited no hTERT mRNA expression. 293 cells 
are known to be telomerase-positive and were used as a positive control. These results 
suggest that the hTERT promoter element can be used to target human cancer. 
 Selective Visualization of Human Cancer Cells In Vitro. To selectively 
enhance GFP transgene expression in human cancer cells, we used a tumor- or 
telomerase-specific replication-selective adenovirus, OBP-301, and a 
replication-deficient Ad-GFP. Schematic DNA structures of OBP-301 and Ad-GFP are 
shown in Fig. 1B. SW620, A549, and H1299 human cancer cells expressed bright GFP 
fluorescence as early as 24 hours after co-infection of Ad-GFP (0.1 MOI) and OBP-301 
(1.0 MOI) (Fig. 2). The fluorescence intensity gradually increased until approximately 
3 days after infection followed by rapid cell death due to the cytopathic effect of 
OBP-301 (data not shown). Ad-GFP infection alone at an MOI of 0.1 caused neither 
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GFP expression nor cytotoxicity in SW620 and A549 cells. Only a faint fluorescence 
could be detected in H1299 cells by 0.1 MOI of Ad-GFP infection, because H1299 cells 
are highly sensitive to adenovirus infection. In contrast, normal human cells, including 
WI-38, NHLF, and HUVEC, were completely negative for GFP expression after 
co-infection with Ad-GFP and OBP-301. These results indicate that Ad-GFP can 
replicate exclusively in human cancer cells in the presence of OBP-301, leading to 
tumor cell-specific GFP fluorescence expression in vitro.  
 Dose-dependent Intensity of Fluorescence by Ad-GFP Injection into Mice. 
To selectively detect tumor tissues in vivo, non-specific GFP transgene expression in 
normal organs must be avoided. We first determined the optimal dose of Ad-GFP that 
could not induce detectable GFP fluorescence in normal tissues. Non-tumor-bearing 
mice were subcutaneously injected with increasing doses of Ad-GFP alone and then 
monitored for fluorescence intensity over time with the CCD non-invasive imaging 
system. As shown in Fig. 3, mice administered 1.3 × 109 and 1.3 × 108 PFU of Ad-GFP 
displayed high and moderate GFP fluorescence signals in the skin, respectively, within 
24 hours post-injection. In contrast, the GFP transgene expression was not visible over 
a 7-day period after injection of 1.3 × 107 or 1.3 × 106 PFU of Ad-GFP. Thus, 108 PFU 
was considered the lowest dose of Ad-GFP that induces non-specific GFP signals in 
normal tissues.  
 Selective Visualization of Subcutaneously Growing Human Tumors In Vivo. 
To further confirm the specificity of the GFP-based fluorescent optical detection of 
tumors in vivo, we performed a set of control experiments. In the control group of 
non-tumor-bearing animals that received subcutaneous injection with 8 × 105 PFU of 
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Ad-GFP plus 8 × 106 PFU of OBP-301, no apparent GFP signals were detected in the 
skin over 7 consecutive days (Fig. 4A). Moreover, injection of Ad-GFP at the density 
of 8 × 105 PFU alone into subcutaneously established SW620 tumors resulted in no 
GFP fluorescence expression for at least 7 days post-injection (Fig. 4B).  
We next examined the kinetics of GFP transgene expression in SW620 and 
A549 tumors after intratumoral injection of 8 × 105 PFU of Ad-GFP and 8 × 106 PFU of 
OBP-301. Treated mice displayed detectable intratumoral signals within 24 hours after 
local delivery of viruses (Fig. 5). Whole-body images of mice showed light spots in the 
tumor area, although complete tumor images were not observed. The fluorescence 
intensity reached maximum levels 3 to 7 days post-injection, and gradually decreased to 
the background fluorescence by 14 days after treatment. When mice were sacrificed 7 
days after intratumoral injection of viruses, GFP expression was confined to the tumor; 
no GFP fluorescence was detected in various normal organs such as liver, kidney, 
spleen, small intestine, brain, heart, pancreas, ovary, and adrenal gland (data not 
shown).  
 Selective Visualization of Pleural Dissemination of Human Lung Cancer 
Cells In Vivo. We also evaluated the potential of GFP-based visualization of A549 
human non-small cell lung cancer cells growing intrathoracically in athymic nu/nu mice. 
We previously reported that, when A549 cells were inoculated into the thoracic space, 
dissemination of tumors appeared in all mice 14 days after tumor injection (17). As 
shown in Fig. 6, the optical CCD imaging of the thoracic cavity following a midsternal 
thoracotomy demonstrated that disseminated tumor nodules in the visceral pleura, 
parietal pleura, diaphragmatic pleura and mediastinum could be detected as light 
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emitting spots by intrathoracic co-injection of 4 × 107 PFU of Ad-GFP and 4 × 107 PFU 
of OBP-301. The large tumors were labeled in spots with GFP fluorescence; small 
nodules, however, could be imaged entirely as intensive GFP signals. Histological 
analysis confirmed the presence of disseminated tumor cells in the sites of fluorescence 
emission (Fig. 6). The thoracic cavity of non-tumor-bearing mice was negative for GFP 
transgene expression (data not shown).  
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DISCUSSION 
 
Gene-based therapeutic strategies, including replacement of defective tumor 
suppressors, enhancement of immune-mediated tumor surveillance, and 
tumor-selective virotherapy, have emerged as promising adjuvants to conventional 
modalities for human cancer (18-21). We previously reported the development of a 
tumor-specific replication-selective adenovirus, OBP-301 or “Telomelysin”, which is 
capable of exclusively replicating in telomerase-positive human cancer cells (12). In the 
current study, we investigated the potential of OBP-301 to visualize human tumors by 
facilitating replication of a GFP-expressing replication-deficient adenovirus, Ad-GFP. 
As reported previously (8), for real-time imaging of growing tumors in live mice, GFP 
appears to be an extremely effective tumor cell marker to identify tumor tissues at a 
single-cell level. A major advantage of GFP labeling is that imaging requires no 
preparative procedures such as contrast agents, substrates, and light-tight boxes as do 
other imaging techniques.  
Elevated levels of telomerase activity are found in the majority of malignancies 
(Fig. 1A) and are believed to play a critical role in tumorigenesis (22). Therefore, 
telomerase-specific OBP-301 was able to selectively compensate the E1 gene products 
for Ad-GFP that lacks E1 proteins in human tumor cells, but not in normal cells. 
However, as the recombinant adenovirus vectors can efficiently infect a wide variety of 
dividing and nondividing cells, and transfer exogenous genes into mammalian cells, 
Ad-GFP infection alone at high concentrations may induce GFP fluorescence 
non-selectively in both tumor and normal cells. Our preliminary experiments 
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demonstrated that Ad-GFP infection alone at less than 1.0 MOI was insufficient to 
induce GFP expression under fluorescence microscopy in most tumor and normal cells 
in vitro (data not shown). We confirmed that co-infection of 0.1 MOI of Ad-GFP and 
1.0 MOI of OBP-301 could express GFP fluorescence selectively in tumor cells, 
although detectable green signals were evident with Ad-GFP infection alone in cells 
sensitive to adenovirus infection, such as H1299 cells (Fig. 2). However, the fact that 
most normal cells are relatively resistant to adenovirus infection suggests that the 
false-positive detection of normal cells is likely to be less frequent.  
It has been reported that 1.6 × 109 PFU of Ad-GFP delivered to various organs 
induced high intensity GFP expression that could be visualized by whole-body imaging 
(11) and, therefore, we determined 107 PFU of Ad-GFP as a suboptimal dose for GFP 
detection in vivo by the dose titration study (Fig. 3). Indeed, intratumoral injection of 8 
× 105 PFU of Ad-GFP plus 8 × 106 PFU of OBP-301 resulted in intensive GFP 
expression in tumors, whereas no GFP signals were detectable by subcutaneous 
administration of these vectors into normal areas (Figs. 4 and 5). CCD imaging 
demonstrated the heterogeneous pattern of GFP expression only in tumors in mice that 
received intratumoral injection of 50 µl of the vector solution, suggesting that the 
vectors might not be able to spread throughout the tumor tissues (Fig. 5). Moreover, the 
green signals in tumors disappeared within 14 days after intratumoral injection of 
Ad-GFP and OBP-301, presumably by the dilution of vectors with tumor cell 
proliferation (Fig. 5). We previously showed that intratumoral injection of OBP-301 
was effective for suppressing the growth of H1299 human lung tumors subcutaneously 
transplanted into nu/nu mice (12); 8 × 106 PFU of OBP-301, however, might be 
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insufficient for growth inhibition of SW620 and A549 tumors. Further studies are 
required to determine optimal doses of the vectors to obtain complete and prolonged 
GFP labeling of solid tumors.  
Progression of non-small cell lung cancer is characterized by the dissemination 
of malignant pulmonary epithelial cells (23). To overcome the poor prognosis of lung 
cancer involving the pleura, innovative methodology for early diagnosis as well as 
treatment is needed. We previously reported that intrathoracic injection of 
replication-deficient adenovirus expressing antisense against heparanase, which is 
associated with metastatic potential, inhibited pleural dissemination of human lung 
cancer cells in an orthotopic murine model (17). These observations suggest that 
intrathoracic administration of adenovirus is capable of infecting disseminated 
neoplastic nodules in the thoracic cavity. Obstacles to effective diagnosis and therapy 
for pleural dissemination include the fact that tumors that are either too small or hidden 
in an internal body location could not be visually detected. Our optical CCD imaging 
was able to visualize tiny foci of pleural dissemination of A549 human lung cancer cells 
with GFP fluorescence after intrathoracic injection of OBP-301 and Ad-GFP, although 
these lesions could not be macroscopically identified (Fig. 6). Several studies have 
demonstrated the utility of CCD imaging to track metastasis and/or dissemination of 
tumor cells that were stably transfected with the GFP gene in small animals (6-10); the 
vector-based strategy in the present study, however, is considered more convenient and 
clinically relevant. If target lesions can be identified during thoracotomy, surgeons are 
capable of removing disseminated tumors. Moreover, a future option may be to develop 
robotic laser therapy for pleural dissemination with an automatic detection tool that 
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chases GFP fluorescence under thoracoscopy.   
The approach is considered to be promising; it also; however, suffers from some 
limitations. For example, tumors existing within organs could not be detected, as it 
requires exposing the tumors to a Xenon lamp. Because the entire tumors were not 
fluorescent except very tiny tumors, the margins of invasive tumors that are not clearly 
encapsulated might go unseen. In addition, the distant metastatic tumors could not be 
visualized by intratumorally or regionally injected OBP-301 and Ad-GFP. As a means 
to circumvent this limitation, the development of the tumor-specific 
replication-selective adenovirus (OBP-401), in which the GFP gene was inserted, has 
allowed systemic administration, leading to the whole-body distribution of the vector, 
thereby detecting distant metastatic lesions with telomerase-specific GFP expression. 
Preclinical studies using OBP-401 are currently underway in our laboratory.   
In conclusion, our data presented here indicate that locoregional injection of 
Ad-GFP plus OBP-301 in combination with highly sensitive CCD imaging might be a 
useful diagnostic strategy for real-time visualization of macroscopically invisible tumor 
tissues. Although the sensitivity and specificity of the method must be assessed by 
further experiments, this technology provides a foundation for future clinical 
application.  
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Figure Legends 
 
Fig. 1  (A) Relative hTERT mRNA expression in human tumor and normal cells 
determined by real-time RT-PCR analysis. The hTERT mRNA expression of A549 
human lung cancer cells was considered as 1.0 and the relative expression level of each 
cell line was calculated against that of A549 cells. (B) Schematic DNA structures of 
OBP-301 and Ad-GFP. OBP-301 contains the hTERT promoter sequence inserted into 
the E3-deleted adenovirus genome to drive transcription of the E1A and E1B 
bicistronic cassette linked by the IRES structure. The Ad-GFP vector contains the GFP 
cDNA driven by the CMV promoter.  
 
Fig. 2  Selective bystander replication of Ad-GFP in the presence of OBP-301 in 
human cancer cells in vitro. Cultured human cancer (SW620 [colorectal], A549 [lung], 
and H1299 [lung]) and normal cells (WI-38, NHLF, and HUVEC) were infected with 
0.1 MOI of Ad-GFP alone or in combination with 1.0 MOI of OBP-301, and 
photographed under the fluorescent microscope for GFP expression 24 hours after 
treatments. × 200 magnification.  
 
Fig. 3  External images of non-tumor-bearing nu/nu mice injected with 
increasing doses of Ad-GFP alone. Non-tumor-bearing mice were subcutaneously 
injected with 1.3 × 106, 1.3 × 107, 1.3 × 108, or 1.3 × 109 PFU of Ad-GFP alone and 
documented as photographs for GFP expression by the CCD non-invasive imaging 
system 24 hours after injection.  
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Fig. 4  (A) External images of non-tumor-bearing mice injected with Ad-GFP 
plus OBP-301. As a control, non-tumor-bearing mice received subcutaneous injection 
with 8 × 105 PFU of Ad-GFP in combination with 8 × 106 PFU of OBP-301, and then 
were assessed for GFP fluorescence 24 hours after administration. As expected, no GFP 
signals were obtained. Left upper panel: macroscopic appearance of mouse. (B) 
External images of SW620 tumor-bearing nu/nu mice injected with Ad-GFP alone. 
Three weeks after subcutaneous inoculation of SW620 tumor cells (5 × 106 
cells/mouse), mice received intratumoral injection of Ad-GFP at the density of 8 × 105 
PFU alone. As expected, no GFP fluorescence expression was detected for at least 7 
days post-injection. Left panels: macroscopic appearance of SW620 tumors; right 
panels: fluorescent detection.  
 
Fig. 5  Time course of external images of subcutaneous SW620 and A549 
tumors after intratumoral injection of Ad-GFP plus OBP-301. Three weeks after 
subcutaneous inoculation of SW620 and A549 tumor cells (5 × 106 cells/mouse), 
Ad-GFP and OBP-301 at the concentrations of 8 × 105 PFU and 8 × 106 PFU, 
respectively, were directly injected into established tumors. The GFP fluorescence 
intensity was monitored for 7 consecutive days under the CCD non-invasive imaging 
system. Left panels: macroscopic appearance of subcutaneous tumors; right panels: 
fluorescent detection.  
 
Fig. 6  Internal images of pleural dissemination visualized by intrathoracic 
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injection of Ad-GFP and OBP-301. Female BALB/c nu/nu mice were intrathoracically 
implanted with 5 x 106 A549 tumor cells. Two weeks later, 4 × 107 PFU/50 µl each of 
Ad-GFP and OBP-301 were injected into the thoracic space. Five days after virus 
injection, mice were sacrificed and their thoracic spaces were examined. Three 
representative mice are shown. Left panel: fluorescent detection; right panel: gross 
appearance of A549 tumors grown orthotopically in the thoracic spaces. Arrows, 
disseminated tiny tumor. Left lower panel: hematoxylin-eosin staining of the lesion of 
fluorescence emission. × 100 magnification.  







